Back to top

Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital

LifeSci Capital analyst Rami Katkhuda downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a $48 price target fter Novartis (NVS...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tourmaline Bio, Inc. (TRML)